MX2025002312A - Terapias combinadas para el tratamiento de linfomas de celulas t con tolinapant, cedazuridina y decitabina - Google Patents

Terapias combinadas para el tratamiento de linfomas de celulas t con tolinapant, cedazuridina y decitabina

Info

Publication number
MX2025002312A
MX2025002312A MX2025002312A MX2025002312A MX2025002312A MX 2025002312 A MX2025002312 A MX 2025002312A MX 2025002312 A MX2025002312 A MX 2025002312A MX 2025002312 A MX2025002312 A MX 2025002312A MX 2025002312 A MX2025002312 A MX 2025002312A
Authority
MX
Mexico
Prior art keywords
combination therapies
tolinapant
cedazuridine
decitabine
treatment
Prior art date
Application number
MX2025002312A
Other languages
English (en)
Spanish (es)
Inventor
Martin John Sims
George Albert Ward
Harold Keer
Aram Oganesian
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2025002312A publication Critical patent/MX2025002312A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2025002312A 2022-08-31 2025-02-26 Terapias combinadas para el tratamiento de linfomas de celulas t con tolinapant, cedazuridina y decitabina MX2025002312A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263374137P 2022-08-31 2022-08-31
PCT/IB2022/060652 WO2024047394A1 (en) 2022-08-31 2022-11-04 Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Publications (1)

Publication Number Publication Date
MX2025002312A true MX2025002312A (es) 2025-04-02

Family

ID=84359488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025002312A MX2025002312A (es) 2022-08-31 2025-02-26 Terapias combinadas para el tratamiento de linfomas de celulas t con tolinapant, cedazuridina y decitabina

Country Status (9)

Country Link
US (1) US20240082286A1 (cg-RX-API-DMAC7.html)
EP (1) EP4580635A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025529240A (cg-RX-API-DMAC7.html)
KR (1) KR20250053870A (cg-RX-API-DMAC7.html)
AU (1) AU2022476674A1 (cg-RX-API-DMAC7.html)
CA (1) CA3266274A1 (cg-RX-API-DMAC7.html)
MX (1) MX2025002312A (cg-RX-API-DMAC7.html)
TW (1) TW202410893A (cg-RX-API-DMAC7.html)
WO (1) WO2024047394A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115368356B (zh) 2013-12-20 2025-05-09 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
CN115368356B (zh) 2013-12-20 2025-05-09 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
LT4069254T (lt) * 2020-02-25 2024-10-10 Otsuka Pharmaceutical Co., Ltd. Kietos geriamosios vaisto formos, apimančios decitabiną ir cedazuridiną

Also Published As

Publication number Publication date
EP4580635A1 (en) 2025-07-09
WO2024047394A1 (en) 2024-03-07
AU2022476674A1 (en) 2025-04-17
KR20250053870A (ko) 2025-04-22
JP2025529240A (ja) 2025-09-04
TW202410893A (zh) 2024-03-16
US20240082286A1 (en) 2024-03-14
CA3266274A1 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
WO2023009834A3 (en) Methods of treating cancer
EP4616902A3 (en) Nerve stimulation for treating migraine and other headache conditions
MX2025005315A (es) Celulas t para usarse en el tratamiento de una enfermedad o afeccion
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
MX2023011856A (es) Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
MX2022003193A (es) Tratamiento de encefalopatia asociada al gen syngap1.
PH12023552792A1 (en) Combination therapies for the treatment of cancer
MX2021009079A (es) Metodos para tratar el mieloma multiple.
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
MX2020011817A (es) Metodos para tratar el linfoma.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
WO2021041539A3 (en) Pyrido-indole analogues as gpx4 inhibitors
ZA202304965B (en) Combination therapy for treating cancer
MX2023006551A (es) Tratamiento de las convulsiones refractarias.
MX2024015041A (es) Fitusiran para el tratamiento de la hemofilia a y b
WO2021041716A3 (en) Therapeutic editing to treat cardiomyopathy
EP4623999A3 (en) Sotorasib for use in the treatment of cancer
MX2023006651A (es) Tratamiento de la hemofilia con fitusirán.
PH12022552489A1 (en) V delta1+ t cells for the treatment of myeloid malignancies
MX2021003734A (es) Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
MX2025015461A (es) Tratamiento combinado
MX2024005589A (es) Combinaciones de lurbinectedina y atezolizumab.